The 10-item Medication Adherence Rating Scale (MARS-10) is a validated, self-report tool used to assess adherence to chronic illnesses due to its applicability. However, its psychometric properties have not been evaluated among cancer patients receiving chemotherapy. This study aimed to determine the psychometric properties of the modified MARS-10 in this population.
Methods
A cross-sectional analytic study was conducted on adults receiving cancer chemotherapy from April to May 2022. Confirmatory factor analysis was used to validate the scale. The internal consistency was determined using composite reliability. Convergent and discriminant validity of the constructs were measured by the average variance extracted and the Heterotrait-Monotrait correlation ratio, respectively. Statistical significance was declared as p-value < 0.05.
Results
Three hundred (n = 300) adults receiving cancer chemotherapy were enrolled in the study. There was a significant difference between the higher and lower adherence scores, t (299) = 95.84, p < 0.001. The four constructs explained 66.6% of the total variance. The composite reliability of constructs one (0.79), two (0.66), three (0.66), and four (0.66) was in the acceptable to good range. The extracted mean-variance was more than 0.50, and the Heterotrait-Monotrait correlation ratio ranged from 0.31–0.83 for all constructs.
Conclusion
This study has established the internal psychometric properties of the modified 10-item Medication Adherence Rating Scale. Therefore, this modified scale is a valuable tool for researchers and has important implications for oncology health promotion, and policymakers where direct adherence measurement to cancer chemotherapy is challenging.
KazibweJTranPBAnnerstedtKS. The household financial burden of non-communicable diseases in low- and middle-income countries: a systematic review. Health Res Policy Syst2021; 19: 96.
2.
World Health Organiazation. Noncommunicable diseases. 2024.
3.
World Health Organization. Key prevention and control interventions for reducing cancer burden in the WHO African region. 2012.
4.
GebrezgiMTTrepkaMJKidaneEA. Barriers to and facilitators of hypertension management in Asmara, Eritrea: patients’ perspectives. J Health Popul Nutr2017; 36: 11.
5.
ShobanaJSemereMSiedM, et al.Prescribing pattern of anti-hypertensive drugs among hypertension patients with cardiac complications in Eritrea. Lat Am J Pharm2013; 32: 745–748.
6.
MufundaJMebrahtuGUsmanA, et al.The prevalence of hypertension and its relationship with obesity: results from a national blood pressure survey in Eritrea. J Hum Hypertens2006; 20: 59–65.
7.
World Health Ranking. Live longer live better; country profile: Eritrea. 2020.
8.
AbduABakreyHHamedM,et al.Non-communicable diseases in Eritrea: a review of challenges, risk factors and public health strategies. Discov Public Health2025; 22: 71.
9.
BrownMTBussellJK. Medication adherence: WHO cares?Mayo Clin Proc2011; 86: 304–314.
10.
SabatéE. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization, 2003.
11.
KalemkerianGPLooBWAkerleyW, et al.NCCN Guidelines insights: small cell lung cancer, version 2.2018. J Natl Compr Canc Netw2018; 16: 1171–1182.
12.
BritoCPortelaMCde VasconcellosMT. Adherence to hormone therapy among women with breast cancer. BMC Cancer2014; 14: 397.
13.
BouwmanLEeltinkCMVisserO, et al.Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation. BMC Cancer2017; 17: 739.
14.
ColNFanaleJEKronholmP. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med1990; 150: 841–845.
15.
InotaiAÁghTMarisR, et al.Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treat Rev2021; 100: 102264.
16.
CheungWY. Difficult to swallow: issues affecting optimal adherence to oral anticancer agents. Am Soc Clin Oncol Educ Book2013; 33: 265–270.
17.
JinJSklarGEMin Sen OhV,et al.Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag2008; 4: 269–286.
18.
AnandUDeyAChandelAKS, et al.Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis2023; 10: 1367–1401.
19.
GatenbyRABrownJS. The evolution and ecology of resistance in cancer therapy. Cold Spring Harbor Perspect Med2020; 10: a040261.
20.
QinSJiangJLuY, et al.Emerging role of tumor cell plasticity in modifying therapeutic response. Signal Transduct Target Ther2020; 5: 228.
21.
ChirgwinJHGiobbie-HurderACoatesAS, et al.Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol2016; 34: 2452–2459.
22.
PutsMTETuHATourangeauA, et al.Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol2014; 25: 564–577.
23.
BellJSAiraksinenMSLylesA, et al.Concordance is not synonymous with compliance or adherence. Br J Clin Pharmacol2007; 64: 710–711.
24.
OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005; 353: 487–497.
25.
SpoelstraSLGivenCW. Assessment and measurement of adherence to oral antineoplastic agents. Semin Oncol Nurs2011; 27: 116–132.
26.
CameronKARossELClaymanML, et al.Measuring patients’ self-efficacy in understanding and using prescription medication. Patient Educ Couns2010; 80: 372–376.
27.
MoharamzadYSaadatHNakhjavan ShahrakiB, et al.Validation of the Persian version of the 8-item Morisky Medication Adherence Scale (MMAS-8) in Iranian hypertensive patients. Glob J Health Sci2015; 7: 173–183.
28.
MoriskyDEDiMatteoMR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol2011; 64: 255–257; discussion 8-63.
29.
LavsaSMHolzworthAAnsaniNT. Selection of a validated scale for measuring medication adherence. J Am Pharm Assoc2011; 51: 90–94.
30.
ZemmourKTinlandABoucekineM, et al.Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: results from the French Housing First experience. Sci Rep2016; 6: 31598.
31.
CohenJLMannDMWisniveskyJP, et al.Assessing the validity of self-reported medication adherence among inner-city asthmatic adults: the Medication Adherence Report Scale for Asthma. Ann Allergy Asthma Immunol2009; 103: 325–331.
32.
StirrattMJDunbar-JacobJCraneHM, et al.Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med2015; 5: 470–482.
33.
ThompsonKKulkarniJSergejewAA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res2000; 42: 241–247.
34.
DemyttenaereKBruffaertsRAlbertA, et al.Development of an antidepressant compliance questionnaire. Acta Psychiatr Scand2004; 110: 201–207.
35.
AchiengCBunaniNKagaayiJ,et al.Adherence to antiretroviral and cancer chemotherapy, and associated factors among patients with HIV–cancer co-morbidity at the Uganda Cancer Institute: a cross sectional study. BMC Public Health2023; 23: 1451.
36.
MoriskyDEGreenLWLevineDM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care1986; 24: 67–74.
37.
HoganTPAwadAGEastwoodR. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med1983; 13: 177–183.
38.
LordFM. Applications of item response theory to practical testing problems. New York: Routledge, 1980.
39.
NguyenTMLa CazeACottrellN. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol2014; 77: 427–445.
40.
FialkoLGaretyPAKuipersE, et al.A large-scale validation study of the Medication Adherence Rating Scale (MARS). Schizophr Res2008; 100: 53–59.
41.
SowunmiOAOnifadePO. Psychometric evaluation of Medication Adherence Rating Scale (MARS) among Nigerian patients with schizophrenia. Niger J Clin Pract2019; 22: 1281.
42.
OwieGOOlotuSOJamesBO. Reliability and validity of the Medication Adherence Rating Scale in a cohort of patients with schizophrenia from Nigeria. Trends Psychiatry Psychother2018; 40: 85–92.
43.
DiamantopoulosASarstedtMFuchsC, et al.Guidelines for choosing between multi-item and single-item scales for construct measurement: a predictive validity perspective. J Acad Mark Sci2012; 40: 434–449.
44.
HairJFHultGTMRingleCM,et al.A primer on partial least squares structural equation modeling (PLS-SEM). 3rd ed.Thousand Oaks: Sage, 2022.
45.
SarstedtMRingleCMHairJF. Partial least squares structural equation modeling. In: Homburg C, Klarmann M and Vomberg A (eds) Handbook of market research. Cham: Springer, 2021, pp.587–632.
46.
HairJHGRingleCSarstedtMA. Primer on partial least squares structural equation modeling (PLS-SEM). Los Angeles: Sage Publications, Incorporated, 2014.
47.
LeechNBarrettKMorganGA. SPSS for intermediate statistics; use and interpretation. 2nd ed. Mahwah, New Jersey, London: Lawrence Erlbaum Associates, Inc., 2005.
48.
AkpolatTAriciMSengulS, et al.Home sphygmomanometers can help in the control of blood pressure: a nationwide field survey. Hypertens Res2018; 41: 460–468.
49.
SarstedtMRingleCMHairJF. Partial least squares structural equation modeling. In: Homburg C, Klarmann M and Vomberg, A (eds) Handbook of market research. Springer, 2011.
50.
BagozziRPYiY. On the evaluation of structural equation models. J Acad Mark Sci1988; 16: 74–94.
51.
HenselerJRingleCMSarstedtM. A new criterion for assessing discriminant validity in variance-based structural equation modeling. J Acad Mark Sci2015; 43: 115–135.
52.
PednekarPPÁghTMalmenäsM, et al.Methods for measuring multiple medication adherence: a systematic review–report of the ISPOR medication adherence and persistence special interest group. Value Health2019; 22: 139–156.
53.
CrossAJElliottRAPetrieK, et al.Interventions for improving medication-taking ability and adherence in older adults prescribed multiple medications. Cochrane Database Syst Rev2020; 5: Cd012419.
54.
BekaluYEWuduMAGashuAW. Adherence to chemotherapy and associated factors among patients with cancer in Amhara Region, Northeastern Ethiopia, 2022. A cross-sectional study. Cancer Control2023; 30: 10732748231185010.
55.
ReshmaVChackoAMAbdullaN, et al.Medication adherence in cancer patients: a comprehensive review. Cureus2024; 16: e52721.
56.
JimmyBJoseJ. Patient medication adherence: measures in daily practice. Oman Med J2011; 26: 155–159.
57.
JacobsJMPensakNASpornNJ, et al.Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract2017; 13: e474–e485.
58.
LamWYFrescoP. Medication adherence measures: an overview. BioMed Res Int2015; 2015: 217047.
59.
DüsingRLottermoserKMengdenT. Compliance with drug therapy-new answers to an old question. Nephrol Dial Transplant2001; 16: 1317–1321.
60.
TalensALÓpez-PintorEGuilabertM, et al.Validation of a scale to assess adherence to oral chemotherapy based on the experiences of patients and healthcare professionals (EXPAD-ANEO). Front Pharmacol2023; 14: 1113898.
61.
ClarosMPMessaCVMGarcía-PerdomoHA. Adherence to oral pharmacological treatment in cancer patients: systematic review. Oncol Rev2019; 13: 402.
62.
ChanAHYHorneRHankinsM,et al.The Medication Adherence Report Scale: a measurement tool for eliciting patients’ reports of nonadherence. Br J Clin Pharmacol2020; 86: 1281–1288.
63.
XuHCaoXZhangY, et al.Continuous improvement of quality management in the fall prevention process for inpatients: a historically controlled study. 2021.
64.
MishraRSharmaSKVermaR, et al.Medication adherence and quality of life among type-2 diabetes mellitus patients in India. World J Diabetes2021; 12: 1740–1749.
65.
World Health Organization. Adherence to long-term therapies, Evidence for action. Geneva, Switzerland: World Health Organization, 2003.
66.
IrwinM. Factors influencing oral adherence: qualitative metasummary and triangulation with quantitative evidence. Clin J Oncol Nurs2013; 19: 6–30.
67.
RuddyKMayerEPartridgeA. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin2009; 59: 56–66.
68.
WeingartSNBrownEBachPB, et al.NCCN Task force report: oral chemotherapy. J Natl Compr Cancer Netw2008; 6: S‐8–S‐10.
69.
SeretnyMCurrieGLSenaES, et al.Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain2014; 155: 2461–2470.
70.
DasARanadiveNKinraM, et al.An overview on chemotherapy-induced cognitive impairment and potential role of antidepressants. Curr Neuropharmacol2020; 18: 838–851.
71.
AluiseCDSultanaRTangpongJ, et al.Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol2010; 678: 147–156.
72.
BernsteinLJEdelsteinKSharmaA,et al.Chemo-brain: an activation likelihood estimation meta-analysis of functional magnetic resonance imaging studies. Neurosci Biobehav Rev2021; 130: 314–325.
73.
LewandowskaARudzkiG. Quality of life of cancer patients treated with chemotherapy. Int J Environ Res Public Health2020; 17: 6938.
74.
GopalanMRKarunakaranVPrabhakaranA,et al.Prevalence of psychiatric morbidity among cancer patients - hospital-based, cross-sectional survey. Indian J Psychiatry2016; 58: 275–280.
